Apellis Pharmaceuticals
APLS · NASDAQ
Price unavailable right now.
No price history for this range.
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 50.5% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q1 FY26 | -$0.3579 | $0.15 | +141.9% |
| Q4 FY25 | -$0.3884 | -$0.47 | −21.0% |
| Q3 FY25 | $1.21 | $1.67 | +38.1% |
| Q2 FY25 | -$0.4785 | -$0.33 | +31.0% |
| Q1 FY25 | -$0.3675 | -$0.74 | −101.4% |
| Q4 FY24 | -$0.3933 | -$0.29 | +26.3% |
| Q3 FY24 | -$0.3061 | -$0.46 | −50.3% |
| Q2 FY24 | -$0.33 | -$0.28 | +15.2% |
Earnings calls
- TD Cowen 46th Annual Health Care Conference
- APLS - Earnings call Q4 2025
- 44th Annual J.P. Morgan Healthcare Conference
- Evercore 8th Annual Healthcare Conference
- Citi Annual Global Healthcare Conference 2025
- Stifel 2025 Healthcare Conference
- APLS - Earnings call Q3 2025
- Baird Global Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.